AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in..

AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with locally advanced..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four..

AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults..

AstraZeneca plc (LON:AZN) has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in..

AstraZeneca plc (LON:AZN) COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. The three approvals authorise Lynparza for:..

AstraZeneca plc (LON:AZN)’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small..

AstraZeneca plc (LON:AZN) Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union for an additional dosing option, 1,500mg fixed dose every four weeks,..

AstraZeneca plc (LON:AZN) has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain,..

AstraZeneca plc (LON:AZN) has announced that positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine..

AstraZeneca plc (LON:AZN) Imfinzi has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications..

AstraZeneca plc (LON:AZN) Brilinta has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF)..

AstraZeneca plc (LON:AZN) has announced that with effect from 1 November 2020, Diana Layfield is appointed as a Non-Executive Director. Diana Layfield is President, EMEA Partnerships..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo Company Limited’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application and has also been granted Priority..

AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) has received acceptance for its supplemental New Drug Application and has also been granted Priority Review in the US for the adjuvant..